Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis☆
Introduction
Amyloidosis is a severe systemic disease. Cardiac amyloidosis (CA) may occur in the three main types of amyloidosis and markedly impacts upon prognosis, with a median survival of < 1 year after the onset of heart failure symptoms until quite recently. The mechanism of death has been traditionally attributed to pulseless electrical activity (PEA) and therefore implantable cardioverter-defibrillator (ICD) implantation has not been considered to be a beneficial therapeutic option.
Recent advances in amyloid specific therapy for light chain (AL) [1] or hereditary amyloidosis transthyretin related (ATTR) amyloidosis, as well as earlier diagnosis at the preclinical stage based on cardiac biomarkers [2] or more sensitive imaging technics [3], [4], [5], have contributed to a significant improvement in CA prognosis. Furthermore, many studies have shown that sustained ventricular arrhythmias (VA) on ECG-holter monitoring [6] or successful termination of VAs with appropriate ICD therapies [7], [8] are not uncommon. However, no robust predictors for malignant VA have been identified. In addition, it has been recently suggested that non-sustained ventricular tachycardia (NSVT) can predict subsequent ICD therapy and should be a risk factor for prophylactic ICD implantation [8]. However, NSVT does not appear to correlate with sudden cardiac death (SCD) or survival in non-implanted CA patients [6].
Cardiac biomarkers seem to predict adverse outcome in AL patients [2], [3], [9], but there is no data to suggest that these biomarkers would predict further VA occurrence [10]. Finally, whether echocardiographic parameters (e.g. strain) associated with worse outcomes [3], [11] would predict malignant VA in CA remain unclear. As a result, the consensus statement from the European Society of Cardiology is that there is insufficient data to provide recommendations on prophylactic ICD implantation in CA patients [12].
We aimed to assess the usefulness of ICD implantation in CA patients with analysis of: i) the occurrence of VA with appropriate ICD therapy and ii) predictors of a combined survival endpoint including death and cardiac transplant.
Section snippets
Patient characteristics
This study was approved by the local institutional review boards, and all patients provided informed consent to participate. All consecutive CA patients undergoing ICD implantation in our centers (5 centers in Paris) were included within this study.
Diagnosis of CA was determined by the presence of a positive endomyocardial biopsy or by a confirmed extra-cardiac histological diagnosis, in addition with thickened cardiac septum (≥ 12 mm by echocardiography with no other cardiac cause of
Patient characteristics
From June 2008 to November 2014, 45 consecutive CA patients (12 AL, 27 ATTR and 6 SSA) met the inclusion criteria and were enrolled in our study. Clinical characteristics are summarized in Table 1. The main indication for ICD placement was primary prevention (84.4%) and 12 patients (26.7%) received a bi-ventricular ICD. LVEF was decreased (< 50%) in 68.9% of cases and ≤ 35% in one third of our population. All but 2 patients had a NT-proBNP > 332 ng/L and interventricular septal wall thickness > 15 mm
Discussion
The main findings of our study were:
- (1)
Appropriate ICD therapies are common (26.7% over 17 months of follow-up) in CA patients while 84% were implanted for primary prevention. Time to first event was short (4.7 months) and all but one patient (92%) experienced the first therapy within the first year post ICD implantation.
- (2)
No specific clinical, echocardiographic or biological criteria could predict ICD therapy but patients with milder heart failure were more likely to experience VA.
- (3)
Mortality from
Conclusion
Malignant VA with subsequent appropriate ICD therapies were frequent (27%) in patients with CA, implanted predominately for primary prevention. No strong predictor was found to predict future appropriate ICD therapies within this population and patients with a more advanced heart failure, especially associated with AL type had a poorer prognosis. Further multicenter prospective studies are clearly necessary to refine ICD indications in CA. Recent advance in amyloidosis therapies might change
Funding sources
This work was supported by the Federation Française de Cardiologie to D. Hamon and V·Algalarrondo and AREMCAR to D. Hamon.
Disclosures
V. Algalarrondo received scholarship funding by St. Jude Medical, Biotronik, Medtronic, Sorin and Boston Scientific.
Acknowledgments
We thank Kamila Djouadi, Karima Ayad and Mounira Kharoubi for helping collecting data and Dr. Tarvinder S. Dhanjal for providing language assistance.
References (31)
- et al.
Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers
J. Am. Coll. Cardiol.
(2012) - et al.
Implantable defibrillators in cardiac amyloidosis
Int. J. Cardiol.
(2013) - et al.
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Heart rhythm.
(2014) - et al.
Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy
Int. J. Cardiol.
(2014) - et al.
Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring
Am. J. Cardiol.
(2009) - et al.
Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis
JACC Cardiovasc. Imaging
(2016) - et al.
Evidence of impaired left ventricular systolic function by doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and doppler echocardiography
Am. J. Cardiol.
(2008) - et al.
Prophylactic pacemaker implantation in familial amyloid polyneuropathy
Heart Rhythm.
(2012) - et al.
Novel potential therapeutic strategies of senile cardiac amyloidosis: heat shock factor 1 blocks senile cardiac amyloidosis via HSPA1A in mouse model
Int. J. Cardiol.
(2015) - et al.
Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II)
J. Am. Coll. Cardiol.
(2005)
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death
Heart rhythm.
Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis
JACC Heart Fail.
Prognostic value of fragmented QRS in cardiac AL amyloidosis
Int. J. Cardiol.
Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings
Int. J. Cardiol.
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
Haematologica
Cited by (71)
Perioperative implications of amyloidosis and amyloid cardiomyopathy: A review for anesthesiologists
2024, Journal of Clinical Anesthesia2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
2023, Journal of the American College of CardiologyElectrocardiographic features and rhythm disorders in cardiac amyloidosis
2023, Trends in Cardiovascular MedicineA Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment
2022, Current Problems in CardiologyCardiac Amyloidosis
2022, Heart Failure Clinics
- ☆
All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
- 1
Both authors contributed equally to this work.
- 2
Present address: UCLA Cardiac Arrhythmia Center, David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, CA, USA. Fax: + 1-310-825-2092.